Health insurers, generic drugmakers and medical device companies are in a bid to win minute but crucial changes as Democratic leaders in Congress declare the final overhaul of the nation's healthcare system.

It is speculated that such firms want to reduce massive taxes that would come up with healthcare reform funds of tens of billions of dollars over the next 10 years to fund the healthcare reforms. However, pharmaceutical and biotech companies stand against such minor tweaking after undergoing deals with lawmakers.

The U.S. House of Representatives and the Senate have taken care of their job by passing bills that would widen the access to health insurance.

Healthcare companies "wouldn't be lobbying so hard right now if they didn't feel like they had a chance to make some changes", said John Shepard, a senior healthcare analyst at the Washington Research Group.

Health insurers are expected to rise to $225 billion in costs through 2019, according to America's Health Insurance Plans (AHIP) President Karen Ignagni, insurers' top lobbyist.

The most significant tax -- a $70 billion one, is expected to raise costs for individual and small group coverage. However, the insurers want to drag it until 2013 or 2014 and widen it further across the country.